A novel prognostic model integrating host vulnerability and tumor biology for elderly patients with diffuse large B-cell lymphoma: the BAMAL score.

Front Oncol · 2026 · PMC12971522 · PMID 41815555

Europe PMC DOI

hedged sentences

0.0010

closest p · 0.0× alpha

0.2700

boldest claim

The sentences

highly significantP<0.001actually significant

The score stratified patients into low- (0–1 points), intermediate- (2–3 points), and high-risk (4–5 points) groups, with highly significant differences in 2-year OS rates of 84.2%, 58.3%, and 16.7%, respectively ( P<0.001 ) ( Table 3 , Figure 2 ).

also in 132,142 other papers

a strong trendP = 0.053so close (0.05 < p ≤ 0.1)

In the Intermediate-Risk Group, patients receiving standard immunochemotherapy (including R-CHOP and R-mini-CHOP) exhibited a strong trend toward superior overall survival compared to those receiving Alternative Regimens (e.g., R-CVP, CHOP) ( P = 0.053 , Median OS: Not Reached vs. 14.6 months).

also in 5,725 other papers

borderline significanceP=0.270not close (p > 0.1)

Notably, the dichotomized LDH (HR 1.993, 95% CI: 0.958–4.149; P=0.065 ) and mFI-5 (HR 1.788, 95% CI: 0.958–3.338; P=0.068 ) showed borderline significance, and Age ≥75 (HR 1.437, 95% CI: 0.754–2.739; P=0.270 ) lost statistical significance.

also in 7,017 other papers

did not reach statistical significanceno p-value reported

The analysis revealed that the differences in AUC between the BAMAL score and the traditional indices did not reach statistical significance (BAMAL vs.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.